A recent meta-analysis suggests there may be no meaningful overall survival benefit from adding hormone therapy to early salvage postoperative radiotherapy (PORT) in patients with prostate cancer who ...

Prostate cancer is one of the most common cancers among men. Many cases grow slowly and may never become life-threatening. Because of this, doctors often recommend a management approach called “active ...

Overview of Peptide Cancer Vaccine MarketThe Global Peptide Cancer Vaccine Market is valued at USD 1.2 Billion in 2024 and is projected to reach a value of USD 15.72 Billion by 2035 at a CAGR ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

Research team at OncoRay identifies MMP11 as a promising biomarker for liquid biopsy in prostate cancer Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In ...

Radiopharmaceutical developer Telix Pharmaceuticals Ltd (ASX:TLX) is expanding its push into AI-enabled cancer imaging ...